Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Merck Sharp & Dohme LLC
AstraZeneca
Chipscreen Biosciences, Ltd.
Shanghai JMT-Bio Inc.
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
AstraZeneca
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
Acerta Pharma BV
BioNTech SE
University College, London
AstraZeneca
Novartis
Eisai Inc.
Children's Cancer Group, China
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Children's Oncology Group
National Cancer Institute (NCI)
SWOG Cancer Research Network
PharmaMar
Regeneron Pharmaceuticals
GlaxoSmithKline
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Takeda
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
AstraZeneca
Hoffmann-La Roche
Children's Oncology Group
Dana-Farber Cancer Institute
Celgene
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche
Regeneron Pharmaceuticals
University of Arkansas